Abstracts tagged "Cohort Study"

Abstract Number: 2338 • ACR Convergence 2025
Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
Aashish Agrawal and Balakrishnan Canchi, Hinduja Hospital, Mumbai, Maharashtra, India
Background/Purpose: The use of combination biologic and targeted synthetic DMARDs remains controversial due to safety concerns, yet may offer benefit in refractory inflammatory arthritis. This…
Abstract Number: 2054 • ACR Convergence 2025
A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-Center Cohort
Ami Purohit¹, Najia Shakoor², Dmitriy Cherny¹ and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) encompass a heterogenous group of autoimmune diseases characterized by inflammation of muscle and other target organs. Muscle biopsy was historically…
Abstract Number: 1721 • ACR Convergence 2025
Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Mario Bautista-Vargas¹, Erika Navarro-Mendoza¹, Jaime Flores-Gouyonnet¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Jose Antonio Meade-Aguilar⁴, Alain Sanchez-Rodriguez⁵, Andrew C. Hanson¹, Cassondra Hulshizer⁶, Cynthia Crowson⁷ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁶Mayo Clinic, Rochester, ⁷Mayo Clinic, Stewartvillle, MN
Background/Purpose: Five-year survival in SLE has plateaued since the 1990s. Most epidemiologic studies pool all SLE phenotypes; It is possible that the excess mortality observed…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 0544 • ACR Convergence 2025
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
Olivier Fakih¹, Anna Molto², Frank Verhoeven¹, Clément Prati¹ and WENDLING Daniel¹, ¹CHU de Besançon, Besançon, Franche-Comte, France, ²Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several…
Abstract Number: 0306 • ACR Convergence 2025
Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
Liubov Arbeeva¹, Virginia Kraus², Richard Loeser³, Yvonne Golightly⁴, Hiroko Enomoto⁵, Masataka Enomoto⁵, Duncan Lascelles⁵ and Amanda Nelson⁶, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²Duke University, Durham, NC, ³University of North Carolina, Chapel Hill, NC, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵North Carolina State University, Raleigh, NC, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Increased intestinal permeability (IP) is common in chronic inflammatory diseases, and can be measured indirectly (e.g., with blood markers such as lipopolysaccharide, LPS), or…
Abstract Number: 2575 • ACR Convergence 2025
Influenza and COVID-19 Vaccination Uptake Among Women with Systemic Rheumatic Diseases in New York City Assessed Between 2022 and 2024
Yongjay Kim¹, Sandhya Kannayiram², Amaya Smole³, Lucy Masto⁴, Neha Nagpal⁵, Naiva Manuela Piatchou Donfack⁵, Deanna Jannat-Khah⁵, Lisa Mandl⁵, Caroline Siegel⁵, Sarah Lieber⁵, Michael Lockshin⁵, Lisa Sammaritano⁵ and Medha Barbhaiya⁵, ¹Hospital for Special Surgery, Englewood Cliffs, NJ, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, ³Hospital for Special Surgery, Brooklyn, NY, ⁴Hospital for Special Surgery, San Francisco, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Women with systemic rheumatic diseases (SRDs), and particularly those on immunosuppressive medications, are at increased risk for serious infections such as influenza and COVID-19.…
Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Marc van Essen¹, Dafne capelusnik², Désirée Van Der Heijde³, Robert Landewé⁴, Wim van Lankveld⁵, Astrid Van Tubergen⁶, Sofia Ramiro⁷ and Annelies Boonen⁸, ¹Maastricht University, Zeist, Netherlands, ²Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁵HAN University of Applied Sciences, Arnhem, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Leiden University Medical Center, Bunde, Netherlands, ⁸Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…
Abstract Number: 2045 • ACR Convergence 2025
Malignancy in Behçet’s Syndrome: A 24-Year Cohort Study In a Non-Endemicand Multiethnic Country
Pedro Araujo¹, Rafael Bassara Macedo², Fabio Specian², Carolina Ejnisman³, Barbara Bayeh³, Percival Sampaio-Barros⁴, Thiago Freitas⁴, Rafael Cordeiro⁵ and Henrique Giardini⁴, ¹Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet’s syndrome (BS) has been associated with an increased risk of malignancy, particularly in studies from endemic regions such as East Asia and the…
Abstract Number: 1710 • ACR Convergence 2025
Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
Andre Lucas Ribeiro¹, Sibel Aydin², Gurjit Kaeley³, Fahmeen J. Afgani⁴, Catherine Bakewell⁵, Marcos Rosemffet⁶, Minna Kohler⁷, Amir Haddad⁸, Maria S. Stoenoiu⁹, Ari Polachek¹⁰, josefina marin¹¹, Arnon Katz¹², Sahil Koppikar¹³ and Lihi Eder¹⁴, ¹Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ³UF COM-J, Ponte Vedra Beach, FL, ⁴Women's College Hospital, Toronto, Canada, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁸Carmel Medical Centre, Haifa, Israel, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²GRAPPA, Seattle, ¹³Women's College Hospital & University of Toronto, Markham, ON, Canada, ¹⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US)…
Abstract Number: 1513 • ACR Convergence 2025
Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Ufuoma Mamoh¹, Queeneth Edwards², Chukwuemelie Okeke³, Justin Riley Lam⁴, Soziema Salia⁵ and Christhopher Haas⁶, ¹Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ²Georgia Southern University, Statesboro, GA, ³Maimonides Medical Center, Brooklyn, NY, ⁴Albert Einstein Medical Center, Philadelphia, PA, ⁵MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore, MD, ⁶MedStar Health Georgetown University (Baltimore) Internal Medicine Program, Baltimore
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that disproportionately affects racial and ethnic minority populations, particularly Black/African American and Hispanic/Latino individuals. In…
Abstract Number: 1180 • ACR Convergence 2025
Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
Rafael Bassara Macedo¹, Pedro Araujo², Fabio Specian¹, Carolina Ejnisman³, Barbara Bayeh³, Percival Degrava Sampaio Barros³, Thiago Freitas⁴, Rafael Cordeiro⁵ and Henrique Giardini⁴, ¹Rheumatology Division, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (USP), Sao Paulo, Sao Paulo, Brazil, ²Universidade de São Paulo, Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil
Background/Purpose: Behçet’s syndrome (BS) is a multisystemic inflammatory condition that affects both genders, although gender-related differences in disease manifestations may vary across regions. Studies report…
Abstract Number: 0701 • ACR Convergence 2025
Exploring Calcinosis On Hand X-Rays In Systemic Sclerosis: a Mayo Clinic Cohort
Maximiliano Diaz Menindez¹, Simran Ravindra Nimal², Michael Pham², Caroyln Harvey³, Leroy W. Griffing² and Vivek Nagaraja², ¹Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ²Mayo Clinic, Scottsdale, AZ, ³Mayo Clinic, Phoenix, AZ
Background/Purpose: Calcinosis is a vexing manifestation in patients with systemic sclerosis (SSc) with a variable prevalence among cohorts. Up to 86% of calcinosis cases are…

« Previous Page
1
…
5
6
7
8
9
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].